Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,180 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04782687 | Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 2 | 73 | US Oncology ResearchINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT05263583 | Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma | active not recruiting | Phase 2 | 14 | Cothera Bioscience, IncINDUSTRY | 2 | Jan 14, 2025 | clinicaltrials |
| A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM |
| active not recruiting |
| Phase 2 |
| 72 |
| Canadian Myeloma Research GroupOTHER |
| 1 |
| Jan 8, 2025 |
| clinicaltrials |
| NCT05838131 | Study of CT071 Injection in RRMM or PPCL | active not recruiting | Early Phase 1 | 20 | Shanghai Changzheng HospitalOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06760936 | Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients(PIXBRIDGE) | active not recruiting | — | 15 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05302648 | To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM | active not recruiting | Early Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 3, 2025 | clinicaltrials |
| NCT04726787 | RadiothErapy priMIng for CAR-T(REMIT) | active not recruiting | N/A | 6 | University College, LondonOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT02315716 | Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma(Cardamon) | active not recruiting | Phase 2 | 281 | University College, LondonOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT03836014 | Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma(CONFIRM) | active not recruiting | Phase 3 | 436 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT02406222 | Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)(MUKseven) | active not recruiting | Phase 2 | 124 | University of LeedsOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT03671018 | A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 422 | Hoffmann-La RocheINDUSTRY | 5 | Nov 29, 2024 | clinicaltrials |
| NCT03153202 | Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | active not recruiting | Phase 1 / Phase 2 | 23 | Joshua BrodyOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT04934475 | MInimal Residual Disease Adapted Strategy(MIDAS) | active not recruiting | Phase 3 | 791 | Intergroupe Francophone du MyelomeNETWORK | 3 | Nov 7, 2024 | clinicaltrials |
| NCT04624958 | Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL | active not recruiting | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT05202782 | Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma | active not recruiting | Phase 2 | 24 | Northwestern UniversityOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT02542657 | Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 30 | Joseph TuscanoOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04049513 | ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)(ENABLE-1) | active not recruiting | Phase 1 | 30 | Malaghan Institute of Medical ResearchOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06547944 | Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)(ZGR in TN CLL) | active not recruiting | Phase 1 | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT00048958 | Cytogenetic Studies in Acute Leukemia and Multiple Myeloma | active not recruiting | — | 9,000 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03245021 | Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A(1stFLOR) | active not recruiting | Phase 1 | 39 | Dr. Eliza HawkesOTHER_GOV | 1 | Jul 30, 2024 | clinicaltrials |
| NCT03980171 | Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma(LEVERAGE) | active not recruiting | Phase 1 / Phase 2 | 50 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT03422393 | Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib | active not recruiting | Phase 1 | 24 | Michael ChoiOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06366802 | Cohort Construction and Prognostic Model Construction for Multiple Myeloma | active not recruiting | — | 1,000 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT04144387 | Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.(CARRISMM) | active not recruiting | N/A | 395 | Intergroupe Francophone du MyelomeNETWORK | 3 | Mar 6, 2024 | clinicaltrials |
| NCT03620578 | DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL(HO152) | active not recruiting | Phase 2 | 97 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 2 | Feb 14, 2024 | clinicaltrials |
| NCT05214183 | Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma(ALTAMIRA) | active not recruiting | Phase 2 | 81 | Nordic Lymphoma GroupNETWORK | 5 | Feb 12, 2024 | clinicaltrials |
| NCT03915184 | Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) | active not recruiting | Phase 1 / Phase 2 | 105 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT03289299 | Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant(ASCENT) | active not recruiting | Phase 2 | 87 | International Myeloma FoundationOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT06154902 | Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel(ABE-DESCART) | active not recruiting | — | 350 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 4, 2023 | clinicaltrials |
| NCT04718883 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma | active not recruiting | Phase 2 | 59 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03673826 | Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM(HO147SMM) | active not recruiting | Phase 2 | 58 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 4 | Nov 1, 2023 | clinicaltrials |
| NCT04808037 | Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma(BelaRd) | active not recruiting | Phase 1 / Phase 2 | 66 | Hellenic Society of HematologyOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT04613557 | Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma(IMMUNICY-1) | active not recruiting | Phase 1 | 18 | Celyad Oncology SAINDUSTRY | 2 | Aug 31, 2023 | clinicaltrials |
| NCT03948035 | Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | active not recruiting | Phase 3 | 576 | Wuerzburg University HospitalOTHER | 2 | May 6, 2023 | clinicaltrials |
| NCT04526834 | Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma(CERTAIN) | active not recruiting | Phase 1 | 21 | Tessa TherapeuticsINDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
| NCT03064867 | Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 65 | Molly GalloglyOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT03742297 | Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years | active not recruiting | Phase 3 | 462 | PETHEMA FoundationOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT02415413 | Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma | active not recruiting | Phase 2 | 90 | PETHEMA FoundationOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02477878 | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | active not recruiting | Phase 1 | 10 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT03606577 | An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients(IFM 2018-04) | active not recruiting | Phase 2 | 50 | Nantes University HospitalOTHER | 1 | Apr 28, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jan 16, 2025source: clinicaltrials